

# AQILION

Helsingborg, Sweden, January 19, 2022

## Press release

### **Aqilion strengthens its operational team in preclinical development**

**Aqilion announced today that Anneli Hällgren has been appointed the new head of preclinical development, including regulatory safety studies. Anneli has worked for the past ten years as a consultant in preclinical drug discovery and will now join the Aqilion team on a part-time basis.**

Anneli Hällgren holds a PhD in physiology from Uppsala University, Sweden, and has more than 20 years of experience in research and development projects with a focus on a variety of indications and disease areas, including inflammatory and autoimmune conditions. Her career began at AstraZeneca, where she worked as a safety pharmacologist and preclinical project manager. Since then, she has held leading positions at companies such as KaroBio, Biolipox and Melacure Therapeutics. Anneli has also belonged to the management of a major EU-funded platform project and has been involved in starting new biotech companies.

“I’m convinced that Anneli Hällgren’s expertise will be extremely valuable for Aqilion’s continued preparations for clinical trials in the company’s phase-1-ready anti-inflammatory program Regulus, as well as the continued preclinical development in the Alnitak program. My colleagues and I are excited about the opportunity to work with Anneli and to benefit from her drive and experience in our operational team,” says Sarah Fredriksson, CEO of Aqilion.

Aqilion focuses on treatments for inflammatory diseases and [the company’s pipeline was updated](#) at the end of 2021. In December, Aqilion acquired the Regulus program (AQ280), which it is now running in-house. Aqilion will initially develop AQ280 as a potential treatment for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus. The aim is to start a Phase 1 safety study with AQ280 in healthy volunteers in 2022, followed by a Phase 2 clinical trial in patients. The Alnitak program has been expanded and resources invested in a project that focuses specifically on compounds with the potential to treat inflammatory conditions of the central nervous system (CNS). Read more about [Aqilion](#) and our [pipeline](#) on our website.

#### **For more information, please contact:**

Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, [sarah.fredriksson@aqilion.com](mailto:sarah.fredriksson@aqilion.com)

#### **About Aqilion**

Aqilion is a biotech company that focuses on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases. The company is mainly active in the early phases of drug discovery, from idea to early clinical development.

Aqilion combines its experience from major pharmaceutical companies with the drive and entrepreneurship of small growth companies. With solid experience of business development in innovative biotech and pharmaceutical companies, Aqilion's experienced team and board have successfully shepherded drugs all the way from discovery to market.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. [www.aqilion.com](http://www.aqilion.com)